Drugs / LYB001
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05928455 | May → Oct 2022 | COVID-19, vaccinia | Guangzhou Patronus Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05552573 | Jul 2022 → Jan 2023 | COVID-19 | Guangzhou Patronus Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05125926 | Dec 2021 → Feb 2023 | COVID-19 | Yantai Patronus Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05602558 | Dec 2022 → Dec 2023 | COVID-19 | Yantai Patronus Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT05137444 | Jan 2022 → Mar 2023 | COVID-19 | Yantai Patronus Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT05683600 | Dec 2022 → Jul 2023 | COVID-19 | Guangzhou Patronus Biotech Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT05664932 | Dec 2022 → Jan 2023 | COVID-19 | Guangzhou Patronus Biotech Co., Ltd. | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYB001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05683600 ↗ |
| Modality | Vaccine | “The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.” NCT05125926 ↗ |
| Route | Intramuscular | “Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56” NCT05125926 ↗ |